Dr Lal PathLabs Hits Fresh 52-Week High as Dubai Expansion Ignites Buying Interest

Shares of $LALPATHLAB witnessed strong buying interest on Tuesday after the company announced its entry into the UAE market through a wholly owned subsidiary in Dubai. The stock surged as much as 11.57% to ₹1,803, marking a fresh 52-week high, before settling with gains of around 1.6%. Notably, the rally extended the stock’s winning streak to four consecutive trading sessions, reflecting growing investor confidence. The incorporation of DR LAL PATHLABS FZCO, backed by an investment of AED 19.135 million, represents a strategic step toward international expansion. The move is expected to strengthen the company’s global presence, diversify revenue streams, and support its long-term growth ambitions. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.